EP
NVCT icon

Essential Partners’s Nuvectis Pharma NVCT Stock Holding History

Essential Partners’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497 Buy
27
+25
+1,250% +$280 ﹤0.01% 2475
2026
Q1 		$15 Buy
+2
New +$17 ﹤0.01% 2831

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Essential Partners's NVCT Position: Q2 2026 in Review

Essential Partners increased its Nuvectis Pharma (NVCT) stake by 1,250% in Q2 2026, buying an estimated $280 and bringing the position to 27 shares worth $497. The position accounts for ﹤0.01% of the portfolio, ranked #2475.

Essential Partners first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Essential Partners held 27 shares of Nuvectis Pharma worth $497 as of Q2 2026.
  • Essential Partners bought 25 Nuvectis Pharma shares in Q2 2026, an estimated $280.
  • Nuvectis Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2475 holding.
  • Essential Partners first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.